Financials · TNYA

Tenaya Therapeutics Inc. (TNYA) financials

For the twelve months ended Sep 30, 2026, Tenaya Therapeutics Inc. reported -$101.78M of net income.

Net income, TTM
-$101.78M
Free cash flow, TTM
-$54.65M
Cash
$66.80M
Market cap
$71.3M
Annual net income-$90.60M
FY2020FY2025
Annual free cash flow-$68.88M
FY2020FY2025

TNYA revenue and earnings growth

TNYA revenueQ3 2026$1.70M

QoQ
+52.9%

TNYA revenue was $1.70M in fiscal Q3 2026 (ended Sep 30, 2026), up 52.9% from the prior quarter.

TNYA net incomeQ3 2026-$18.94M

TNYA net income was -$18.94M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.27M a year earlier. For the full fiscal 2025 it was -$90.60M, compared with -$111.13M in fiscal 2024.

TNYA EPSQ3 2026-$0.08

TNYA diluted EPS was -$0.08 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2025 it was -$0.59.

TNYA free cash flowQ3 2026-$17.68M

TNYA free cash flow was -$17.68M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.63M a year earlier. For the full fiscal 2025 it was -$68.88M, compared with -$91.53M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Research and development$68.61M$86.74M$98.04M$94.54M$54.39M$31.10M
Selling, general and admin$24.72M$29.21M$33.16M$31.08M$18.41M$7.81M
Operating income-$93.33M-$115.95M-$131.19M-$125.62M-$72.81M-$38.91M
Pre-tax income-$90.60M-$111.13M-$124.08M-$123.67M-$72.72M-$38.40M
Income tax$0$0$0$0$0$0
Net income-$90.60M-$111.13M-$124.08M-$123.67M-$72.72M-$38.40M
EPS, basic-$0.59-$1.31-$1.68-$2.76-$4.10-$39.50
EPS, diluted-$0.59-$1.31-$1.68-$2.76-$4.10-$39.50
Diluted shares153.0M84.8M73.8M44.8M17.7M972,091

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Cash and equivalents$100.55M$4.32M$45.68M$95.27M$38.13M$128.53M
Short-term investments-$57.12M$58.96M$91.25M$213.17M-
Current assets$105.59M$67.38M$111.58M$193.75M$255.36M$129.96M
Total assets$146.92M$119.94M$170.51M$278.94M$314.19M$148.16M
Current liabilities$15.44M$15.97M$22.73M$24.25M$21.77M$5.04M
Total liabilities$23.66M$27.09M$31.09M$35.57M$35.66M$8.72M
Shareholders' equity$123.27M$92.85M$139.42M$243.38M$278.53M-$81.31M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Operating cash flow-$68.26M-$90.50M-$102.07M-$104.42M-$60.81M-$35.45M
Capital expenditures$618.0K$1.02M$1.24M$20.63M$25.12M$9.76M
Free cash flow-$68.88M-$91.53M-$103.31M-$125.05M-$85.93M-$45.21M
Investing cash flow$56.08M$1.13M$48.72M$83.65M-$238.56M-$7.01M
Financing cash flow$108.41M$47.75M$4.05M$77.77M$208.97M$147.27M
Share repurchases----$13.0K$1.0K
Stock-based compensation$13.05M$16.50M$15.31M$11.47M$2.95M$741.0K
Depreciation and amortization$8.44M$8.47M$8.69M$6.47M$2.96M$2.48M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Return on equity-73.5%-119.7%-89.0%-50.8%-26.1%-
Return on assets-61.7%-92.7%-72.8%-44.3%-23.1%-25.9%
Current ratio6.844.224.917.9911.7325.78

Source: XBRL data Tenaya Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TNYA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TNYA---$101.78M-$71.3M
AMGN$38.90B+8.2%$9.39B24.1%$240.11B
GILD$30.99B+6.5%-$3.86B-12.5%$209.59B
MRNA$2.52B+13.1%-$2.79B-110.5%$79.63B
ARGX$4.25B+88.6%$1.29B30.4%$58.42B
BIIB$10.30B+2.3%$347.50M3.4%$37.16B
RVMD$0--$1.13B-$34.57B
BNTX€2.87B+4.3%-€1.14B-39.6%$20.92B
EXEL$2.50B+9.1%$885.14M35.5%$16.66B

TNYA FAQ

5 questions
  • Is TNYA profitable?
    No. Tenaya Therapeutics Inc. reported a net loss of $101.78M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TNYA have?
    Tenaya Therapeutics Inc. reported $66.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is TNYA free cash flow?
    Tenaya Therapeutics Inc. generated -$54.65M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$54.41M less capital expenditures.
  • When did TNYA last report financial results?
    The latest statements here come from Tenaya Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this TNYA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Tenaya Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.